

Subject: Treatment Guidelines - BLS
Narcan® Nasal Spray (naloxone)


Associated Policies:

- I. Class
 - A. Narcotic antagonist.
- II. Indications
 - A. Environment is suspicious for use of opioids.
 - B. Victim is unconscious/poorly responsive and respiratory rate appears slow (<12) or shallow/inadequate; or victim is unconscious and not breathing.
- III. Therapeutic Effect/Mechanism of Action:
 - A. Naloxone is chemically similar to narcotics; however, it has only antagonistic properties. Naloxone competes for opiate receptors in the brain and displaces narcotic molecules from opiate receptors. It can reverse respiratory depression from narcotic overdose.
- IV. Contraindications
 - A. Absolute:
 - 1. Known hypersensitivity.
 - 2. An advanced airway is in place and patient is being adequately ventilated.
 - 3. Infants < 30 days or newly born
- V. Precautions
 - A. Narcan® (Naloxone) Nasal Spray should be administered cautiously to patients who are known or are suspected to be physically dependent on narcotics. Abrupt and complete reversal by naloxone can cause withdrawal type effects.
- VI. Side Effects:
 - A. Hypotension
 - B. Nausea and vomiting.
- VII. Administration and Dosage-
Route for BLS Providers will only include Intranasal(IN) Narcan® (Naloxone) Nasal Spray.
 - A. Adult: 4mg intranasal via auto device. May be repeated every 2-3 minutes if no improvement.

Subject: Treatment Guidelines – BLS
Narcan® Nasal Spray (naloxone)

Associated Policies:

- B. Pediatric: (>30 days of age) 4mg intranasal via auto device. May be repeated every 2-3 minutes if no improvement.

Approved: 

Approved as to Form: 